Fractyl Labs, a Lexington, Massachusetts-based startup developing treatments for diabetes, has raised $44 million in Series D financing from a slew of VC firms, including GV, True Ventures, the IDO Fund, General Catalyst, Bessemer Venture Partners, Domain Associates, Mithril Capital Management, Emergent Medical Partners, L.P., and Deerfield Management Company, L.P. Fractyl has been working on… Read More
Permalink — http://feedproxy.google.com/~r/Techcrunch/~3/srXniWEn6bA/
URL of source article.
Date — November 30, 2017 12:00 pm
Publish date of source article.
Source — http://feeds.feedburner.com/TechCrunch
URL of RSS feed.
Advertisements
